Peter Attia· MD
what we know about fatty liver disease nazle nav any way that you study it the translation from preclinical to clinical let alone phase one to phase three does not it's not always born out with the biology given the beauty of the liver and it homeostasis so I want to talk a little a little bit about glp1 agonists um at least the two most popular ones that are out there today so semaglutide and tritide um obviously they have a profound impact on weight loss uh they generally tend to have a very favorable impact on insulin sensitivity as well so it would seem to me that one could make the case today that the most effective drug we have for treating Naf D formerly Naf D and Nash are indeed these drugs